{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:15:57Z","timestamp":1778177757057,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"DOI":"10.7759\/cureus.108439","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T17:53:50Z","timestamp":1778176430000},"source":"Crossref","is-referenced-by-count":0,"title":["Pemigatinib-Associated Psoriasis in a Patient With Cholangiocarcinoma"],"prefix":"10.7759","author":[{"given":"Abigail G","family":"Hendrie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Hadj Smaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter A","year":"2020","unstructured":"Menter A, Gelfand JM, Connor C, et al.. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020, 82:1445-86. 10.1016\/j.jaad.2020.02.044","journal-title":"J Am Acad Dermatol"},{"key":"ref2","article-title":"Psoriasis","author":"Nair PA","year":"2026","unstructured":"Nair PA, Badri T. Psoriasis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01381-0","article-title":"Triggers for the onset and recurrence of psoriasis: a review and update","volume":"22","author":"Liu S","year":"2024","unstructured":"Liu S, He M, Jiang J, et al.. Triggers for the onset and recurrence of psoriasis: a review and update. Cell Commun Signal. 2024, 22:108. 10.1186\/s12964-023-01381-0","journal-title":"Cell Commun Signal"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.015","article-title":"Triggering psoriasis: the role of infections and medications","volume":"25","author":"Fry L","year":"2007","unstructured":"Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007, 25:606-15. 10.1016\/j.clindermatol.2007.08.015","journal-title":"Clin Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S126727","article-title":"Drug-induced psoriasis: clinical perspectives","volume":"7","author":"Balak DM","year":"2017","unstructured":"Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl). 2017, 7:87-94. 10.2147\/PTT.S126727","journal-title":"Psoriasis (Auckl)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13552","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines","volume":"26","author":"Lacouture ME","year":"2021","unstructured":"Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, Abou-Alfa G. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist. 2021, 26:e316-26. 10.1002\/onco.13552","journal-title":"Oncologist"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0726","article-title":"Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma","volume":"17","author":"Merz V","year":"2021","unstructured":"Merz V, Zecchetto C, Melisi D. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future Oncol. 2021, 17:389-402. 10.2217\/fon-2020-0726","journal-title":"Future Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/10985549.2024.2399766","article-title":"Inflammatory mediators suppress FGFR2 expression in human keratinocytes to promote inflammation","volume":"44","author":"Ferrarese L","year":"2024","unstructured":"Ferrarese L, Koch M, Baumann A, et al.. Inflammatory mediators suppress FGFR2 expression in human keratinocytes to promote inflammation. Mol Cell Biol. 2024, 44:489-504. 10.1080\/10985549.2024.2399766","journal-title":"Mol Cell Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17428","article-title":"Validation of the Peak Pruritus-Numerical Rating Scale in patients with chronic plaque psoriasis: results from a phase 2 study","volume":"63","author":"Draelos ZD","year":"2024","unstructured":"Draelos ZD, Bushmakin AG, Ghosh P, Xenakis J, Cappelleri JC. Validation of the Peak Pruritus-Numerical Rating Scale in patients with chronic plaque psoriasis: results from a phase 2 study. Int J Dermatol. 2024, 63:e375-82. 10.1111\/ijd.17428","journal-title":"Int J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027535","article-title":"Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry","volume":"9","author":"Strober B","year":"2019","unstructured":"Strober B, Greenberg JD, Karki C, et al.. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019, 9:e027535. 10.1136\/bmjopen-2018-027535","journal-title":"BMJ Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113587","article-title":"Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: a joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies","volume":"200","author":"Parisi A","year":"2024","unstructured":"Parisi A, Delaunay B, Pinterpe G, et al.. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: a joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies. Eur J Cancer. 2024, 200:113587. 10.1016\/j.ejca.2024.113587","journal-title":"Eur J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal L","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, et al.. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023, 388:228-39. 10.1056\/NEJMoa2206834","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/434176-pemigatinib-associated-psoriasis-in-a-patient-with-cholangiocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T17:53:51Z","timestamp":1778176431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/434176-pemigatinib-associated-psoriasis-in-a-patient-with-cholangiocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.108439","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}